Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis

Nephrology

Volumn 22, Issue 9, 2017, Pages 706-711

  Goel, Amit ^a   Bhadauria, Dharmendra Singh ^a   Kaul, Anupma ^a   Prasad, Narayan ^a   Gupta, Amit ^a   Sharma, Raj Kumar ^a   Rai, Praveer ^a   Aggarwal, Rakesh ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

chronic hepatitis C; chronic kidney disease; chronic viral hepatitis; end stage renal disease; maintenance dialysis

Indexed keywords

ANTIBIOTIC AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; GENOTYPE; HUMAN; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; ADOLESCENT; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECT; DRUG MONITORING; GENETICS; HEMODIALYSIS; HEPACIVIRUS; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROCEDURES; RECURRENT DISEASE; TIME FACTOR; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RECURRENCE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 85026904506     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12833     Document Type: Article

References (22)

1. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int. Suppl. 2008; 73 (109): S1–99.
2. Corouge M, Vallet-Pichard A, Pol S. HCV and the kidney. Liver Int. 2016; 36 (Suppl 1): 28–33.
3. Ozer Etik D, Ocal S, Boyacioglu AS. Hepatitis C infection in hemodialysis patients: A review. World J Hepatol 2015; 7 (6): 885–95.
4. Hsu YH, Hung PH, Muo CH et al. Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease: An 8-Year Nationwide Cohort Study in Taiwan. Medicine (Baltimore) 2015; 94 (47): e2113.
5. EASL. Recommendations on Treatment of Hepatitis C 2015. J. Hepatol. 2015; 63 (1): 199–236.
6. Hepatitis C. guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015; 62 (3): 932–54.
7. Pockros PJ, Reddy KR, Mantry PS et al. Efficacy of Direct-acting Antiviral Combination for Patients with HCV Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology 2016; 150 (7): 1590–8.
8. Desnoyer A, Pospai D, Le MP et al. Sofosbuvir-containing regimen for HCV infection in hemodialysis patients: 400 mg daily or only on the day of hemodialysis. J. Hepatol. 2016; 65 (1): 40–7.
9. Roth D, Nelson DR, Bruchfeld A et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015; 386 (10003): 1537–45.
10. Perumpail RB, Wong RJ, Ha LD et al. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl. Infect. Dis. 2015; 17 (2): 275–8.
11. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130 (1): 231–264 quiz 214–37.
12. Liu CH, Liu CJ, Huang CF et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut 2015; 64 (2): 303–11.
13. Liu CH, Huang CF, Liu CJ et al. Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann. Intern. Med. 2013; 159 (11): 729–38.
14. Fabrizi F, Dixit V, Messa P et al. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. J. Viral Hepat. 2014; 21 (10): 681–9.
15. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347 (13): 975–82.
16. Kwo PY. Response-guided therapy for HCV. Gastroenterol. Hepatol. (N Y) 2011; 7 (1): 43–5.
17. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N. Engl. J. Med. 2011; 365 (11): 1014–24.
18. Ferenci P. Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow. Best Pract. Res. Clin. Gastroenterol. 2012; 26 (4): 463–9.
19. Lawitz EJ, Membreno FE. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects. J. Gastroenterol. Hepatol. 2014; 29 (8): 1574–81.
20. Duseja A, Choudhary NS, Gupta S et al. Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre. Trop. Gastroenterol. 2012; 33 (3): 189–92.
21. Seth AK, Chandra A, Puri P et al. Genotype 1 hepatitis C virus infection predominates among patients with chronic kidney failure and renal allograft recipients in India. Indian J. Gastroenterol. 2009; 28 (4): 159–60.
22. Amarapurkar DN, Patel ND, Kirpalani AL. Monotherapy with peginterferon alpha-2b {12 kDa} for chronic hepatitis C infection in patients undergoing haemodialysis. Trop. Gastroenterol. 2007; 28 (1): 16–18.